| 001 | 164052 | ||
| 005 | 20240229123203.0 | ||
| 024 | 7 | _ | |a 10.1007/s11307-020-01548-y |2 doi |
| 024 | 7 | _ | |a pmid:33063132 |2 pmid |
| 024 | 7 | _ | |a 1536-1632 |2 ISSN |
| 024 | 7 | _ | |a 1860-2002 |2 ISSN |
| 024 | 7 | _ | |a altmetric:115614092 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2020-02220 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Ristau, J. |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Impact of Primary Staging with Fibroblast Activation Protein Specific Enzyme Inhibitor (FAPI)-PET/CT on Radio-Oncologic Treatment Planning of Patients with Esophageal Cancer. |
| 260 | _ | _ | |a New York [u.a.] |c 2020 |b Springer |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1609155089_26352 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2020 Dec;22(6):1495-1500 |
| 520 | _ | _ | |a Quinoline-based ligands targeting cancer-associated fibroblasts have emerged as promising radiopharmaceuticals in different tumor entities. The aim of this retrospective study was to explore the potential of FAPI-PET/CT in the initial staging of esophageal cancer patients and its usefulness in radiotherapy planning as a first clinical analysis.Seven patients with treatment-naive esophageal cancer underwent FAPI-PET/CT. Tracer uptake was quantified by standardized uptake values (SUV)max and (SUV)mean. Six patients received definitive and one neoadjuvant (chemo)radiation therapy. Endo-esophageal clipping, the gold standard to define tumor margins not delineable per CT, was performed in three patients.Primary tumors demonstrated high FAPI uptake with a median SUVmax of 17.2. Excellent tumor-to-background ratios resulted in accurate target volume delineation and were found in perfect match with clipping. Detection of regional lymph node metastases facilitated the use of simultaneous integrated boost radiotherapy plans for these patients.FAPI-PET/CT may be beneficial for the management of esophageal cancer particularly in planning radiotherapy, but further research is necessary to increase patient number and statistical reliability. |
| 536 | _ | _ | |a 315 - Imaging and radiooncology (POF3-315) |0 G:(DE-HGF)POF3-315 |c POF3-315 |f POF III |x 0 |
| 542 | _ | _ | |i 2020-10-15 |2 Crossref |u https://creativecommons.org/licenses/by/4.0 |
| 542 | _ | _ | |i 2020-10-15 |2 Crossref |u https://creativecommons.org/licenses/by/4.0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Giesel, F. L. |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Haefner, M. F. |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Staudinger, F. |b 3 |
| 700 | 1 | _ | |a Lindner, T. |b 4 |
| 700 | 1 | _ | |a Merkel, A. |b 5 |
| 700 | 1 | _ | |a Schlittenhardt, J. |b 6 |
| 700 | 1 | _ | |a Kratochwil, C. |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Choyke, P. L. |b 8 |
| 700 | 1 | _ | |a Herfarth, K. |0 P:(DE-He78)ea5c703d5f5cf5f1c26a34b38a5056dc |b 9 |u dkfz |
| 700 | 1 | _ | |a Debus, J. |0 P:(DE-He78)8714da4e45acfa36ce87c291443a9218 |b 10 |u dkfz |
| 700 | 1 | _ | |a Haberkorn, U. |0 P:(DE-He78)13a0afba029f5f64dc18b25ef7499558 |b 11 |u dkfz |
| 700 | 1 | _ | |a Koerber, S. A. |0 P:(DE-HGF)0 |b 12 |
| 773 | 1 | 8 | |a 10.1007/s11307-020-01548-y |b Springer Science and Business Media LLC |d 2020-10-15 |n 6 |p 1495-1500 |3 journal-article |2 Crossref |t Molecular Imaging and Biology |v 22 |y 2020 |x 1536-1632 |
| 773 | _ | _ | |a 10.1007/s11307-020-01548-y |0 PERI:(DE-600)2079211-6 |n 6 |p 1495-1500 |t Molecular imaging and biology |v 22 |y 2020 |x 1536-1632 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:164052 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)ea5c703d5f5cf5f1c26a34b38a5056dc |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)8714da4e45acfa36ce87c291443a9218 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)13a0afba029f5f64dc18b25ef7499558 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-315 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Imaging and radiooncology |x 0 |
| 914 | 1 | _ | |y 2020 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2020-01-03 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MOL IMAGING BIOL : 2018 |d 2020-01-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2020-01-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2020-01-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |d 2020-01-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2020-01-03 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2020-01-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2020-01-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2020-01-03 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |d 2020-01-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2020-01-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2020-01-03 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2020-01-03 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)E060-20160331 |k E060 |l E060 KKE Nuklearmedizin |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)E050-20160331 |k E050 |l E050 KKE Strahlentherapie |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E060-20160331 |
| 980 | _ | _ | |a I:(DE-He78)E050-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| 999 | C | 5 | |a 10.1016/j.critrevonc.2019.03.008 |9 -- missing cx lookup -- |1 A Fiorentino |p 117 - |2 Crossref |u Fiorentino A, Laudicella R, Ciurlia E, Annunziata S, Lancellotta V, Mapelli P, Tuscano C, Caobelli F, Evangelista L, Marino L, Quartuccio N, Fiore M, Borghetti P, Chiaravalloti A, Ricci M, Desideri I, Alongi P (2019) Positron emission tomography with computed tomography imaging (PET/CT) for the radiotherapy planning definition of the biological target volume: PART 2. Crit Rev Oncol Hematol 139:117–124. https://doi.org/10.1016/j.critrevonc.2019.03.008 |t Crit Rev Oncol Hematol |v 139 |y 2019 |
| 999 | C | 5 | |a 10.1200/JCO.2004.01.083 |9 -- missing cx lookup -- |1 HL van Westreenen |p 3805 - |2 Crossref |u van Westreenen HL, Westerterp M, Bossuyt PM, Pruim J, Sloof GW, van Lanschot JJ et al (2004) Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 22(18):3805–3812. https://doi.org/10.1200/JCO.2004.01.083 |t J Clin Oncol |v 22 |y 2004 |
| 999 | C | 5 | |a 10.1002/cncr.10330 |9 -- missing cx lookup -- |1 H Kato |p 921 - |2 Crossref |u Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H, Tsukada K, Oriuchi N, Inoue T, Endo K (2002) Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer. 94(4):921–928 |t Cancer. |v 94 |y 2002 |
| 999 | C | 5 | |2 Crossref |u Zimmermann C, Babich JW, Joyal J, Marquis J, Wang J-C, inventors (2010) Molecular Insight Pharmaceuticals, Inc., assignee. Selective seprase inhibitors. U.S. patent application 2010/0098633 A1. April 22, 2010 |
| 999 | C | 5 | |a 10.1186/s41181-019-0069-0 |9 -- missing cx lookup -- |1 T Lindner |p 16 - |2 Crossref |u Lindner T, Loktev A, Giesel F, Kratochwil C, Altmann A, Haberkorn U (2019) Targeting of activated fibroblasts for imaging and therapy. EJNMMI Radiopharm Chem 4(1):16. https://doi.org/10.1186/s41181-019-0069-0 |t EJNMMI Radiopharm Chem |v 4 |y 2019 |
| 999 | C | 5 | |a 10.2967/jnumed.118.224469 |9 -- missing cx lookup -- |1 A Loktev |p 1421 - |2 Crossref |u Loktev A, Lindner T, Burger EM, Altmann A, Giesel F, Kratochwil C, Debus J, Marmé F, Jäger D, Mier W, Haberkorn U (2019) Development of fibroblast activation protein-targeted radiotracers with improved tumor retention. J Nucl Med 60(10):1421–1429. https://doi.org/10.2967/jnumed.118.224469 |t J Nucl Med |v 60 |y 2019 |
| 999 | C | 5 | |a 10.2967/jnumed.119.237016 |9 -- missing cx lookup -- |1 SA Koerber |p 1331 - |2 Crossref |u Koerber SA, Staudinger F, Kratochwil C, Adeberg S, Haefner MF, Ungerechts G, Rathke H, Winter E, Lindner T, Syed M, Bhatti IA, Herfarth K, Choyke PL, Jaeger D, Haberkorn U, Debus J, Giesel FL (2020) The role of FAPI-PET/CT for patients with malignancies of the lower gastrointestinal tract - first clinical experience. J Nucl Med 61:1331–1336. https://doi.org/10.2967/jnumed.119.237016 |t J Nucl Med |v 61 |y 2020 |
| 999 | C | 5 | |a 10.2967/jnumed.118.210443 |9 -- missing cx lookup -- |1 T Lindner |p 1415 - |2 Crossref |u Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, Jäger D, Mier W, Haberkorn U (2018) Development of Quinoline-based Theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med 59(9):1415–1422. https://doi.org/10.2967/jnumed.118.210443 |t J Nucl Med |v 59 |y 2018 |
| 999 | C | 5 | |a 10.2967/jnumed.118.210435 |9 -- missing cx lookup -- |1 A Loktev |p 1423 - |2 Crossref |u Loktev A, Lindner T, Mier W, Debus J, Altmann A, Jager D et al (2018) A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med 59(9):1423–1429. https://doi.org/10.2967/jnumed.118.210435 |t J Nucl Med |v 59 |y 2018 |
| 999 | C | 5 | |a 10.2967/jnumed.118.215913 |9 -- missing cx lookup -- |1 FL Giesel |p 386 - |2 Crossref |u Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, Debus J, Jäger D, Flechsig P, Altmann A, Mier W, Haberkorn U (2019) (68)Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers. J Nucl Med 60(3):386–392. https://doi.org/10.2967/jnumed.118.215913 |t J Nucl Med |v 60 |y 2019 |
| 999 | C | 5 | |a 10.2967/jnumed.119.227967 |9 -- missing cx lookup -- |1 C Kratochwil |p 801 - |2 Crossref |u Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Röhrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor HU, Jäger D, Debus J, Haberkorn U, Giesel FL (2019) (68)Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med 60(6):801–805. https://doi.org/10.2967/jnumed.119.227967 |t J Nucl Med |v 60 |y 2019 |
| 999 | C | 5 | |a 10.3322/caac.21551 |9 -- missing cx lookup -- |1 RL Siegel |p 7 - |2 Crossref |u Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34. https://doi.org/10.3322/caac.21551 |t CA Cancer J Clin |v 69 |y 2019 |
| 999 | C | 5 | |a 10.1016/j.radonc.2016.04.042 |9 -- missing cx lookup -- |1 CY Chen |p 136 - |2 Crossref |u Chen CY, Li CC, Chien CR (2016) Does higher radiation dose lead to better outcome for non-operated localized esophageal squamous cell carcinoma patients who received concurrent chemoradiotherapy? A population based propensity-score matched analysis. Radiother Oncol 120(1):136–139. https://doi.org/10.1016/j.radonc.2016.04.042 |t Radiother Oncol |v 120 |y 2016 |
| 999 | C | 5 | |a 10.1007/s00259-020-04769-z |9 -- missing cx lookup -- |1 H Chen |p 1820 - |2 Crossref |u Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, Wei J, Wu S, Zhao L, Luo Z, Lin X, Xie C, Sun L, Lin Q, Wu H (2020) Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging 47:1820–1832. https://doi.org/10.1007/s00259-020-04769-z |t Eur J Nucl Med Mol Imaging |v 47 |y 2020 |
| 999 | C | 5 | |a 10.1148/rg.255045122 |9 -- missing cx lookup -- |1 C Love |p 1357 - |2 Crossref |u Love C, Tomas MB, Tronco GG, Palestro CJ (2005) FDG PET of infection and inflammation. Radiographics. 25(5):1357–1368. https://doi.org/10.1148/rg.255045122 |t Radiographics. |v 25 |y 2005 |
| 999 | C | 5 | |a 10.1111/jth.12396 |9 -- missing cx lookup -- |1 S Uitte de Willige |p 2029 - |2 Crossref |u Uitte de Willige S, Malfliet JJ, Janssen HL, Leebeek FW, Rijken DC (2013) Increased N-terminal cleavage of alpha-2-antiplasmin in patients with liver cirrhosis. J Thromb Haemost 11(11):2029–2036. https://doi.org/10.1111/jth.12396 |t J Thromb Haemost |v 11 |y 2013 |
| 999 | C | 5 | |a 10.1016/j.ejphar.2017.05.022 |9 -- missing cx lookup -- |1 C Egger |p 64 - |2 Crossref |u Egger C, Cannet C, Gerard C, Suply T, Ksiazek I, Jarman E et al (2017) Effects of the fibroblast activation protein inhibitor, PT100, in a murine model of pulmonary fibrosis. Eur J Pharmacol 809:64–72. https://doi.org/10.1016/j.ejphar.2017.05.022 |t Eur J Pharmacol |v 809 |y 2017 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::